The KEYNOTE 407 study related to combined immunochemotherapy in squamous metastatic NSCLC showed an improvement in PFS and OS but also the effect on PD-L1 expression [10, 11]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.